Gritstone Oncology, Inc. (Nasdaq: GRTS) has announced the pricing of its underwritten public offering of 6,500,000 shares of common stock at a public offering price of $11.50 per share, before underwriting discounts and commissions.
Gritstone Oncology Inc. (Nasdaq: GRTS) has announced the pricing of its underwritten public offering of 6,500,000 shares of common stock at a public offering price of $11.50 per share, before underwriting discounts and commissions. As detailed in the company press release, gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Gritstone Oncology, are expected to be approximately $74.8 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on April 29, 2019, subject to customary closing conditions.
Latham & Watkins LLP represents Gritstone Oncology, Inc. in the offering with a corporate team led from the firm’s Silicon Valley office by partnersBrian Cuneo and Alan Mendelson with associates Alexander White and Sarah Greibrok. Advice was also provided on intellectual property matters by partner Christopher Hazuka with associate Peggy Ni in Silicon Valley; on benefits and compensation matters by partner James Metz with associate James Robinson in Silicon Valley; on tax matters by partner Grace Lee with associate Jessica Chen in San Francisco; on regulatory matters by partners Ben Haas and Elizabeth Richards in Washington, D.C. with counsel Betty Pang in San Francisco and associate Barrett Tenbarge in Washington, D.C.
